Liabilities / Assets
53rd percentile
Tied with the lowest-debt nonprofits in its peer group.
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.00x
Liabilities / Revenue
54th percentile
Tied with the lowest-debt nonprofits in its peer group.
Net Margin
97th percentile
Higher net margin than 97% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
78th percentile
Faster asset growth than 78% of similar nonprofits.
Revenue Growth
63rd percentile
Faster revenue growth than 63% of similar nonprofits.
Balance Sheet
Assets
Up$46,807
Up $13,433 (+40%) from 2020
Net Assets
-
No earlier filing loaded for comparison.
Liabilities
$0
No earlier filing loaded for comparison.
Revenue And Expenses
Revenue
Up$14,724
Up $2,465 (+20%) from 2020
Expenses
Down$1,291
Down $5,795 (-82%) from 2020
Net Income
Up$13,433
Up $8,260 (+160%) from 2020
Historical Trend
Filing Detail Status
This 2021 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2021 to Dec 31, 2021
Mission and Program Overview
Mission
Cure first mission is to accelerate discovery of targeted and less toxic treatment for cancer using innovative technologies.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2021 • Form 990EZSummary only. Only limited summary data is available for this year.
- Assets
- $46,807
- Liabilities
- $0
- Net assets
- -
- Revenue
- $14,724
- Expenses
- $1,291
- Net income
- $13,433